International Society of Liquid Biopsy shared a post on X:
“Early Monitoring of Plasma KRAS G12C with Digital PCR in Advanced NSCLC
Key Insights:
Frontline therapy: Immune-checkpoint inhibitors (ICI) and targeted strategies in KRAS-positive NSCLC.
Early monitoring: ctDNA dynamics correlate with response and survival outcomes.
Findings: Elevated ctDNA in liver metastases, >3 metastatic sites, and high allele frequency linked to worse prognosis.
Significance: Plasma DNA reduction aligns with objective responses (p = 0.01).
Discover More.”
Authors: Andrea De Giglio et al.
Luis E. Raez shared this post on X, adding:
“It’s very important to consider liquid biopsies to monitor tumor response.”
Luis Raez is the Medical Director and Chief Scientific Officer at Memorial Cancer Institute, part of Memorial Healthcare System. He specializes in treating lung and head and neck cancers and leads the Thoracic Oncology Program as Director.
Dr. Raez is also a clinical professor of medicine at Florida International University (FIU), a research professor at Florida Atlantic University (FAU), and a visiting professor of medicine at Cayetano Heredia University (UPCH) in Peru.